First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC
Phase III Study Being Initiated For Two-Drug Regimen
Executive Summary
Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.
You may also be interested in...
Boehringer Buys Abexxa To Boost Cancer Pipeline
The latest in a series of deals that Boehringer Ingelheim has inked in the oncology space will see the German family-run firm acquire US biotech Abexxa.
Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab
Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.
Mirati’s KRAS Inhibitor Gains Edge On Efficacy, But Safety Trails Amgen’s Competing Drug
Mirati’s adagrasib seems to have better efficacy data while Amgen’s sotorasib has the safety advantage, but oncologists aren’t issuing a verdict yet.